tradingkey.logo

CORRECTED-Cannabis firm Canopy's Q1 revenue beats estimates

ReutersAug 8, 2025 11:30 AM


Overview

  • Canopy Growth fiscal Q1 revenue rises 9% yr/yr, beating analyst expectations

  • Gross margin declines to 25% from 35% due to product mix shift

  • SG&A expenses down 21% yr/yr, achieving C$17 mln in cost savings


Outlook

  • Supply chain improvements to boost cannabis supply in Europe H2 FY2026

  • Company to launch new Storz & Bickel vaporizer H2 2025

  • Canopy Growth aims to improve cannabis gross margins H2 FY2026

  • Company focuses on expanding retail distribution in FY2026


Result Drivers

  • CANADA ADULT-USE - Revenue increased 43% yr/yr driven by distribution expansion and demand for new products

  • COST SAVINGS - Achieved C$17 mln of planned C$20 mln annualized savings target, reducing SG&A expenses by 21% yr/yr

  • PRODUCT MIX SHIFT - Gross margin decreased due to shift towards higher-cost manufactured products and lower sales in Poland


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

Beat

C$72.1 mln

C$64.50 mln (4 Analysts)

Q1 Adjusted EBITDA

-C$8 mln

Q1 Gross Margin

25.0%


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Canopy Growth Corp is C$2.15, about 32.6% above its August 7 closing price of C$1.45

Press Release: ID:nBw2CwHJRa

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI